Osteonecrosis of the Femoral Head in an HIV-Infected Patient on a Protease Inhibitor-Sparing Antiretroviral Combination

Chiquini MC†, Eyer-Silva WA†*, Albuquerque CF†, Ramos MRF†, da Silva GAR†, Oliveira RPB†, Pinto JFC† and Ferry FRA†

†Department of Biological and Health Sciences, Federal University of the State of Rio de Janeiro, Rio de Janeiro, Brazil

Received Date: 04 Mar 2017
Accepted Date: 02 Jun 2017
Published Date: 12 Jun 2017

Abstract

Physicians who care for HIV-infected patients are being challenged to deal with osteonecrosis as an emerging complication. The role of protease inhibitors (PI) as a risk factor remains to be better defined. Osteonecrosis of the femoral head is a debilitating disease that usually leads to destruction of the hip joint and requires total hip arthroplasty as a definitive treatment. We present the case of a 34 year-old female patient who developed osteonecrosis of the femoral head 4 years after initiation of a successful PI-sparing antiretroviral combination. Health care providers should have a low threshold for osteonecrosis investigation in HIV-infected subjects.

Keywords: Antiretroviral therapy; HIV Infection; Osteonecrosis

Introduction

Physicians who care for human immunodeficiency virus (HIV)-infected patients are being challenged to deal with osteonecrosis as an emerging complication. Osteonecrosis, or avascular necrosis, is the death of bone tissue, including the bone marrow, usually as a result of impaired arterial blood supply [1,2]. The most vulnerable site is the femoral head. It is a debilitating disease that usually leads to destruction of the hip joint and requires total hip replacement as definitive treatment. A myriad of systemic factors are associated with osteonecrosis, mainly hypercholesterolemia, glucocorticoid administration, and trauma. Other important predisposing factors include excessive alcohol intake, connective tissue disorders, intravenous drug use, deep sea diving or other hyperbaric conditions, coagulopathy, and hemoglobinopathies [3-6].

It has been estimated that the incidence of osteonecrosis among HIV-infected patients is 45 times greater than would be expected in the general population [1,2]. Reports of HIV-associated osteonecrosis are available since the early 1990’s [1,7-9]. Since some patients had no known risk factors, it has been suggested that HIV infection itself may stand as a novel predisposing condition. Some authors suggested that antiretroviral therapy (ART) that include a protease inhibitor (PI) play a role in the development of osteonecrosis through mechanisms such as its tendency to cause hyperlipemia [10-14]. Others found no difference in overall PI use among cases and controls [15]. It has also been suggested that osteonecrosis could be the result of immunologic recovery after initiation of ART [16], which would place it as a novel feature of the immune reconstitution inflammatory syndrome. However, some HIV-infected patients develop osteonecrosis while on a non PI-including combination [17] or even before initiation of ART [7]. We report on the case of a patient who developed osteonecrosis 4 years after initiation of PI-sparing ART.

Case Presentation

A 34 year-old female patient with a recent diagnosis of HIV infection started follow up at our outpatient unit in June 2008. She had oral candidiasis and had lost weight in the previous months. Pneumocystis pneumonia was treated with trimethoprim-sulfamethoxazole and a short course of corticosteroids. Her CD4+ cell count was 341 cells/mm³. ART composed of three reverse transcriptase inhibitors (zidovudine, lamivudine and nevirapine) was started. Plasma viral load could not be obtained prior to treatment initiation. Since then, all viral load measurements yielded undetectable levels.
Four years later she developed new-onset left hip pain that worsened with walking. An antalgic gait was evident. The patient had no history of smoking, use of alcohol or illicit drugs, hematological or coagulation abnormalities. She informed that her only medications were the antiretroviral combination composed of zidovudine, lamivudine and nevirapine. Active and passive mobilization of the left coxo-femoral articulation, as well as internal and external hip rotation, were limited by pain. At this point the CD4 cell count was 775 cells/mm³. Physical therapy and non-steroidal anti-inflammatory drugs were started. Pain progressively worsened during the ensuing 2 years. Laboratory examinations showed an LDL cholesterol in the upper normal limit (131 mg/dl) and was otherwise unremarkable. Plain radiographs and computed tomography scans revealed changes consistent with osteonecrosis of the left femoral head: loss of sphericity of both femoral heads, more advanced on the left, subchondral collapse, left femoral head subluxation, subchondral cyst formation, and sclerosis. Magnetic resonance imaging (MRI) showed that the antero-medial aspect of the left femoral head had an osteochondral lesion of low signal intensity on T1-weighed images (Figure 1A), surrounded by a rim of hyperintensity signal on short tau inversion recovery (STIR) images, corresponding to extensive bone infarct. The lesion measured 3.5 cm × 1.8 cm × 2 cm.

Total hip arthroplasty was performed (Figure 1B) in July 2015. She experienced an uneventful recovery. Pathological examination (Figure 1C and 1D) revealed trabecular bone necrosis, overlying articular cartilage degeneration, marrow fibrosis and fat infiltration. No evidence of osteomyelitis was found.

**Discussion**

There is no specific features on history or physical examination to indicate a diagnosis of osteonecrosis. Pain and disability may result from microfracture, damage to articular surfaces, and swelling of the bone marrow [1]. In early cases, a high index of suspicion is necessary. MRI is considered the imaging method with the highest sensitivity and specificity, whereas computed tomography is the most sensitive for detecting subchondral fractures [18]. Given their low cost and simplicity, plain radiographs are the most appropriate initial test in the management of hip pain. In advanced disease, a subchondral fracture, also known as the "crescent sign" is suggestive of osteonecrosis [18].

HIV-associated osteonecrosis is probably a multifactorial disorder. HIV infection and ART are likely contributing factors by themselves. One study found a marked increase in the annual incidence of osteonecrosis in HIV-infected patients between 1990 and 2000 [19]. The frequency of osteonecrosis increased from 1.6 per 1000 AIDS patients during 1993–1996 to 14 per 1000 patients in 1997–2000, which seems to have a temporal relationship with the availability of PI [19]. In fact, a prospective MRI-based study found an unexpectedly high incidence of osteonecrosis of the femoral head in 15 (4.4%) out of 339 asymptomatic HIV-infected patients [20].

A major issue is the possibility of drug interactions with the PI ritonavir, commonly used as a booster to other PIs. It is known that ritonavir significantly increases the systemic exposure to corticosteroids [21,22]. Some case reports have been published on the emergence of osteonecrosis in PI-treated HIV-infected patients who have been prescribed inhaled corticosteroids [23,24]. Our patient had no other traditional risk factors for the development of osteonecrosis, other than an LDL cholesterol in the upper limit of normality. She was a non smoker and was not on any other drug besides her PI-sparing ART. It seems unlikely that the short course of glucocorticoids administered 4 years earlier has played a role in the development of osteonecrosis.

Health care providers should be aware of this emerging complication of HIV infection and should offer HIV testing to all patients with a diagnosis of osteonecrosis. A low threshold to osteonecrosis investigation in HIV-infected patients should be exercised, since its incidence is probably underestimated. The role of ART as a predisposing factor to osteonecrosis requires additional investigations. Even though many authors have suggested an association with the use of PI, it should be stressed that osteonecrosis may occur under a PI-sparing regimen, as has occurred in the present case, and even prior to initiation of ART, as previously reported in the literature.

**References**

9. Matos MA, Alencar RW, Matos SS. Avascular necrosis of the femoral head...


